Nocira Awarded Fifth Patent for its Migraine Treatment Technology

Nocira LLC has been granted its fifth U.S. patent for its proprietary approach to migraine treatment.
 
“This growing U.S. patent portfolio, plus others abroad, reflects and confirms Nocira’s pioneering leadership— via our visionary inventors—for ear pressure-based therapeutic neuromodulation,” said Jim Peacock, CEO of Nocira. 
 
Nocira was the first to treat migraines by applying air pressure changes in the ears, and has continued to develop and evaluate the patented approach in a series of clinical studies for acute migraine treatment, since over half a decade ago. That experience evolved into Nocira’s current “Automated Variable Pressure Insufflation” (AVPI) approach that automatically controls changing pressure patterns in the ear. That approach, and others, are included in the issued Nocira patent portfolio. However, according to Peacock, “The AVPI platform is clearly the superior approach. In particular, the automated ear pressure controls provide significant advantages under each of the three pillars for any successful medical device—safety, performance, and adoptability.”  
 
This is further explained by Dr. David George, who is one of the named inventors within the Nocira patent portfolio, a co-founder and the chief science officer of Nocira, and also a neurorehabilitation expert. “AVPI controls and varies patterns of applied pressure changes in the ear in order to optimally stimulate key nerve receptors and related therapeutic pathways into areas of the brain that regulate pain. This enhances the speed and extent of relief. Yet, those same controls also limit those same pressures to remain comfortable and within published ear pressure safety ranges. To our knowledge, this is also the first personalized migraine therapy that customizes aspects of the treatment to optimize results for each specific migraine attack in each patient,” he said.
 
The investigational Nocira AVPI system includes a small hand-held or pocketable device connected to comfortable earpieces, similar to standard in-ear audio earbuds. It is also controlled via Bluetooth by a downloadable mobile phone app and intuitive user interface.
 
“The Nocira AVPI device is clearly designed not only for performance, but also for wide consumer appeal and adoptability,” added Peacock. “It looks and feels more like a new tech/audio device and app that is actually enjoyed and wanted, vs. a medical treatment device that is only used because it is needed. Along those lines, this is also incredibly easy and even enjoyable to use. It allows the distressed migraine sufferer to just sit back, relax, and enjoy a passive, relieving, even comfortable and pleasurable therapeutic experience.”
 
Nocira continues to pursue additional patents and conduct additional clinical research, with plans to submit for regulatory pre-market review and clearance for its patented, non-invasive AVPI migraine solution next year.
 
Nocira is a pre-market medical device company developing safe and rapidly effective, drug-free treatments for migraines and other neurological disorders. Nocira’s initial focus, via its non-invasive Automated Variable Pressure Insufflation (AVPITM) device system and therapy, applies controlled pressure changes in the external ear canal to harness the unique pressure-responsive sensory and neuropathway physiology associated with the ear for therapeutic neuromodulation. The Nocira AVPI system and related methods are the subject of issued patents and pending patent applications, both in the United States and other territories, owned exclusively by Nocira LLC. 
 
Nocira’s Automated Variable Pressure Insufflation device system is an investigational device limited by U.S. law to investigational use only.